Paper Details

  1. Home
  2. Paper Details

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Author: , ClelandJohn G F, Di LenardaAndrea, HanrathPeter, KomajdaMichel, LubsenJacobus, LutigerBeatrix, MetraMarco, Poole-WilsonPhilip A, RemmeWillem J, ScherhagArmin, SkeneAllan, SwedbergKarl, Torp-PedersenChristian

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Carvedilol is more effective than metoprolol in extending survival for patients with chronic heart failure, systolic dysfunction, and optimal background treatment with diuretics and angiotensin-converting enzyme inhibitors.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Beta blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome. METHODS: In a m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(03)13800-7

データ提供：米国国立医学図書館（NLM）

Carvedilol vs. Metoprolol: A Race to the Finish Line

This research, conducted as a randomized controlled trial, aimed to compare the effects of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Both medications are beta-blockers, known to reduce mortality in patients with heart failure. The study found that carvedilol significantly extended survival compared to metoprolol, with a consistent reduction in all-cause mortality across different subgroups. However, there was no significant difference between the two medications in terms of the composite endpoint of mortality or all-cause admission. The incidence of side-effects and drug withdrawals was also similar for both treatments.

A Triumph for Carvedilol in the Heart Failure Race

Carvedilol emerges as the winner in this race against heart failure, showing a significant advantage over metoprolol in extending survival. This is akin to a fleet-footed camel navigating the desert, outpacing its competitors to reach the finish line. While both beta-blockers offer benefits, carvedilol appears to provide a more favorable outcome for patients with chronic heart failure.

A Long and Winding Road to Recovery

The study highlights the importance of choosing the right medication for heart failure, a complex condition with various treatment options. Much like a journey across a vast desert, the path to recovery from heart failure can be long and challenging. This research provides valuable insights for physicians and patients alike, guiding them toward a more effective treatment strategy.

Dr. Camel's Conclusion

This research reminds us that the path to recovery is not always straightforward, much like a camel caravan encountering shifting sands. While both carvedilol and metoprolol offer benefits for heart failure patients, this study suggests that carvedilol might provide a more favorable outcome in terms of extending survival. The research underscores the importance of individualized treatment strategies tailored to the specific needs of each patient.

Date :
  1. Date Completed 2003-07-23
  2. Date Revised 2023-10-24
Further Info :

Pubmed ID

12853193

DOI: Digital Object Identifier

10.1016/S0140-6736(03)13800-7

Related Literature

Article Analysis
・Side Effects of carvedilol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.